CClinicalTrials.gg
CompletedNCT05848518EJerSA-COVIDUpdated Mar 19, 2024

Exercise for Health in Patients With Post-acute Sequelae of COVID-19

An interventional study of Rehabilitation program in Long COVID, sponsored by Campus docent Sant Joan de Déu-Universitat de Barcelona. Completed at 1 site in Spain. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by Campus docent Sant Joan de Déu-Universitat de Barcelona · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

Background: Many patients with COVID-19 present the so-called post-acute sequelae of COVID-19 such as fatigue, post-stress discomfort, dyspnea, headache, pain mental impairment, incapacity to perform daily physical tasks ant exercise intolerance. This study aims to investigate the effects of different exercise programs on physical and mental fitness, physical condition and biomarkers of the immune system and oxidative stress in older COVID-19 survivors. Methods: The sample will be made up of 120 eligible participants, over the age of 60 years who have had COVID-19 disease and are survivors and present persistent COVID-19 symptomatology diagnosed by the corresponding physician. The participants will be randomly assigned to the experimental groups: supervised endurance group (SEG, n = 30), supervised strength group (SSG, n = 30), supervised concurrent group (SCG, n = 30), which will perform the corresponding exercise program 3 days a week compared to the control group (CG, n = 30), which will not carry out a supervised exercise program. The design of this project will include assessment of cardiorespiratory fitness, muscle fitness, pain and mental health, and biomarkers of inflammation and oxidative stress.

Read the detailed description

This project will carry out a randomized controlled trial to determine what type of supervised exercise program is the most effective compared with a control group (CG): supervised endurance group (SEG), supervised strength group (SSG), supervised concurrent group (strength and endurance) (SCG) and CG. The project will be divided into 3 subprojects and performed in coordination by three institutions as follows:

i) Subproject of the consolidated research group on pain, physical activity, nutrition and health (Acronym: DAFNiS) of the Campus Sant Joan de Deu. University of Barcelona. "Effects of a physical exercise program (aerobic, strength or combined/concurrent) on muscle fitness, pain and mental health in older COVID-19 survivors".

ii) Subproject of the Hospital of Matar: "Evaluation of cardiorespiratory and muscular fitness in older COVID-19 survivors".

iii) Subproject of the Department of Physiology and Immunology. University of Barcelona. "Evaluation of biomarkers of inflammation and oxidative stress in older COVID-19 survivors".

The sample will be made up of 120 eligible participants, over the age of 60 years who have had COVID-19 disease and are survivors and present persistent COVID-19 symptomatology with sequelae of fatigue, muscle weakness, pain, difficulty in performing daily life activities, etc. diagnosed by the corresponding physician. The participants will be recruited from Hospital of Matar. Candidates fulfilling the study inclusion criteria will provide signed informed consent prior to inclusion.

To calculate the sample size of this project a type 1 (α) error of 5% and a 95% confidence interval with a level of precision (d = 0.095) was established for the test of proportional hypotheses resulting in a sample size of n= 108 persons, increased by 10% (rounded up to n=120) to compensate for possible dropouts along the study period.

To know the sample size more precisely in the hypothesis test of means it will be necessary to carry out a pilot study which will provide the size of effect and statistical power (0.80), determine the analysis to perform, obtain delta values in the units corresponding to the principal study variable as well as know the standard deviation.

Program of supervised exercise The intervention will consist in a program of supervised physical exercise performed 3 times a week for 12 weeks. For the planning and control of the exercise program the progressive individualized planning model will be applied based on the subjective perception of effort and cardiorespiratory parameters (heart rate and ventilatory threshold determined in the evaluation tests) of the participants. This program has been used by our research group in previous studies for improving cardiorespiratory and muscle fitness. The basis of this periodization model establishes an initial period of individualization to obtain the personal parameters used for the training load

The COVID-19 survivors will be randomly assigned to 3 programs of supervised exercise :

  1. Program of endurance exercise. The program of supervised endurance exercise will consist in walking for 1 hour 3 times a week. The intensity (step speed) will gradually be increased each week (approx. 5%) according to the perception of the participant. A pulsometer will be used to determine the safe range of heart rate at which the participant should perform.
  2. Program of strength exercise This will consist in performing a program of traditional strength 1 hour 3 times a week. Circuit training methodology will be used (10 exercises) alternating muscle groups of the upper and lower extremities and trunk. The initial series be of 1 exercise, evolving to up to 3-4 along the program based on the individual adaptation of the individual. The intensity (load applied) will be gradually increased each week while the recovery times between each exercise activity will be reduced (approx. 5%) according to the perception of the participant. A pulsometer will be used to determine the safe range of heart rate at which the participant should perform.
  3. Program of concurrent exercise (endurance and strength) The participants will perform 1 hour of concurrent exercise, combining walking (20 minutes) and the strength program for 40 minutes, maintaining the same instructions explained previously in each exercise program.
  4. Control group The control group will not carry out any supervised exercise program but will maintain their same habits of daily life activities.

Process of evaluation To determine the effects of the exercise program, an initial evaluation will be made before beginning the exercise program to assess the initial status of the participants (Pre). This evaluation will be compared with the evaluation made at the end of the intervention program (Post) at 12 weeks

02

Conditions studied

  • Long COVID

Keywords

  • rehabilitation programs
  • endurance exercise
  • resistance exercise
  • cardiopulmonary exercise testing
  • muscle strength assessment
  • quality of life
  • elderly people
  • severe acute respiratory syndrome coronavirus 2
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 120 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Campus docent Sant Joan de Déu-Universitat de Barcelona is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Persons of both sexes (and different expression of gender) older than 60 years of age.
  • No history of physical diseases and no disease or disability that limits participation in the exercise program or precludes the corresponding measurement/evaluations.
  • Be able to communicate without difficulty.
  • Be able to understand the objectives of the project and provide informed consent. In this case, the consent form will be signed.
  • Not taking any medication that can affect normal performance of the exercise program and the evaluations

Exclusion criteria

Exclusion Criteria:

  • Having acute or terminal disease or any other disease that may affect the normal practice of a supervised exercise program and the corresponding evaluations.
  • Consumption of alcohol or drugs.
  • Be performing any type of activity that may interfere in carrying out the supervised exercise program or the evaluations.
  • Not completing the study once initiated or wishing to participate in the control group.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Concurrent rehabilitation program

    Endurance plus resistance exercises

    Other: Rehabilitation program

  • Experimental
    Endurance rehabilitation program

    Endurance exercises

    Other: Rehabilitation program

  • Experimental
    Strength rehabilitation program

    Resistance exercises

    Other: Rehabilitation program

  • No intervention
    Control group

    No exercise

Interventions

  • OtherRehabilitation program

    The participants will be randomly assigned to the experimental groups: supervised endurance rehabilitation program (SEG, n = 30), supervised strength rehabilitation program (SSG, n = 30), supervised concurrent rehabilitation program (SCG, n = 30), and control group (CG, n = 30)

06

What researchers measure

Primary outcomes

  1. Cardiorespiratory fitness: absolute oxygen uptake

    absolute oxygen uptake (peak VO2) in L/min

    Time frame: 1 week per group

  2. Cardiorespiratory fitness: relative oxygen uptake

    relative oxygen uptake (peak VO2) in mL/kg/min

    Time frame: 1 week per group

  3. Cardiorespiratory fitness: ventilation

    minute ventilation (VE) in L/min.

    Time frame: 1 week per group

  4. Cardiorespiratory fitness: ventilatory equivalent for oxygen

    Ventilatory equivalent for oxygen (VE/VO2)

    Time frame: 1 week per group

  5. Cardiorespiratory fitness: ventilatory equivalent for carbon dioxide

    Ventilatory equivalent for carbon dioxide (VE/VCO2)

    Time frame: 1 week per group

  6. Cardiorespiratory fitness: respiratory exchange ratio

    Respiratory exchange ratio (RER)

    Time frame: 1 week per group

  7. Cardiorespiratory fitness: End-tidal partial pressure

    End-tidal partial pressure of oxygen and carbon dioxide (PetO2 and PetCO2, respectively) in mmHg.

    Time frame: 1 week per group

  8. Muscular fitness: Sit and stand test

    Sit and stand test for 30 seconds. The number of times in 30 seconds the participant can completely stand up from a seated position with the back straight and the feet on the floor without pushing with the arms will be counted.

    Time frame: 1 week per group

  9. Muscular fitness: countermovement jump

    Countermovement jumps: Flight Height in cm

    Time frame: 1 week per group

  10. Muscular fitness: countermovement test

    Countermovement jumps: power output of the lower extremities in watts

    Time frame: 1 week per group

  11. Muscular fitness: Upper limb strength

    This will be evaluated with the bicep curl test made with a 2 kg weight for women and a 4 Kg weight for men. The number of elbow curls made in 30 seconds with each upper limb will be counted.

    Time frame: 1 week per group

  12. Muscular fitness: hand grip strength

    Hand grip strength: Force in Newtons Motor Agility/Dynamic balance: This will be evaluated with the 8-foot up and go test. The best of two attempts will be registered

    Time frame: 1 week per group

  13. Muscular fitness: Motor Agility/Dynamic balance

    Motor Agility/Dynamic balance: This will be evaluated with the 8-foot up and go test. The best of two attempts will be registered in seconds

    Time frame: 1 week per group

  14. Muscular fitness: Isokinetic strength test

    The isokinetic knee flexor and extensor test: peak torque in N m

    Time frame: 1 week per group

  15. Muscular fitness: Isokinetic strength testing

    The isokinetic knee flexor and extensor test: power output in Watts

    Time frame: 1 week per group

  16. Body composition: fat mass

    Fat mass will be assessed by bioelectrical impedance analysis in kg and percentage of body weight.

    Time frame: 1 week per group

  17. Body composition: fat free mass

    Fat free mass will be assessed by bioelectrical impedance analysis in kg and percentage of body weight.

    Time frame: 1 week per group

  18. Body composition: muscle mass

    Muscle mass will be assessed by bioelectrical impedance analysis in kg and percentage of body weight.

    Time frame: 1 week per group

  19. Concentration of oxidative stress biomarkers: thiobarbituric acid reactive substances

    Determination of oxidized lipids by the thiobarbituric acid reactive substances (TBARS) in mmols (fluorimetry technique).

    Time frame: 1 week per group

  20. Concentration of oxidative stress biomarkers: Advanced Oxidation Protein Products

    Determination of oxidized proteins by the Advanced Oxidation Protein Products (AOPP) in nmol Cl-T/mg protein, (colorimetry technique)

    Time frame: 1 week per group

  21. Concentration of oxidative stress biomarkers: nitrites and nitrates

    Determination of nitrites and nitrates (colorimetry) in nmol/mL

    Time frame: 1 week per group

  22. Concentration of biomarkers of antioxidant enzymes: superoxide dismutase

    superoxide dismutase (SOD) in units/mL

    Time frame: 1 week per group

  23. Concentration of biomarkers of antioxidant enzymes: catalase

    catalase (CAT) in units/mL

    Time frame: 1 week per group

  24. Concentration of biomarkers of antioxidant enzymes: glutathion peroxidase

    Glutathion peroxidase (GPx) in units/mL.

    Time frame: 1 week per group

  25. Concentration of inflammation biomarkers: Interleukines

    Interleukin 6 and 10 (IL-6 and IL-10) in ng/mL

    Time frame: 1 week per group

  26. Concentration of inflammation biomarkers: adiponectin

    adiponectin in mg/L

    Time frame: 1 week per group

  27. Concentration of biomarkers of inflammation: Tumor necrosis factor

    Tumor Necrosis Factor-alpha in pg/mL

    Time frame: 1 week per group

  28. Evaluation of the degree of pain using the pupillometer: pupil diameter

    basal and maximum diameter of the pupil in mm

    Time frame: 1 week per group

  29. Evaluation of the degree of pain using the pupillometer:variation of pupil

    percentage of variation of pupil diameter in %

    Time frame: 1 week per group

  30. Evaluation of the degree of pain using the pupillometer: pupil variation

    variation of the pupil in mm

    Time frame: 1 week per group

  31. Evaluation of the degree of pain using the pupillometer: Intensity of reflex of dilatation

    Intensity of reflex of dilatation, latency.

    Time frame: 1 week per group

  32. Evaluation of the degree of pain with a pressure algometer: algometers

    Pain will be quantified with a pressure algometer + pupillometer in older COVID-19 survivors. A pressure algometer allows the application of a controlled and quantifiable nociceptive stimulus on a body surface. Algometers apply a pressure stimulus that can be useful for applying a standardized painful stimulus, having a different nature from that applied with the pupillometer which is a stimulus of electric origin.

    Time frame: 1 week per group

  33. Mental health

    Psychosocial variables will be evaluated using the Hospital Anxiety and Depression Scale (HADS), which is made up of 7 items for anxiety and depression. Each item of the anxiety subscale (HADS-A) and the depression subscale (HADS-D) will be scored on a scale of 4 points from 0 (none) to 3 (much more). The highest scores indicate the highest levels of anxiety or depression

    Time frame: 1 week per group

07

Study locations

1 site
  • Campus Docent Sant Joan de Déu. Universitat de Barcelona
    Sant Boi De Llobregat, Barcelona 08830, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05848518
Lead sponsor
Campus docent Sant Joan de Déu-Universitat de Barcelona
Collaborators
Hospital de Mataró, University of Barcelona
Responsible party
Manuel Vicente Garnacho Castano (Coordinator of the DAFNiS research group, Campus docent Sant Joan de Déu-Universitat de Barcelona) — Principal investigator
First posted
May 8, 2023
Start date
May 15, 2023
Primary completion
Sep 30, 2023
Completion
Jan 31, 2024
Last update
Mar 19, 2024

Study contacts

Manuel V Garnacho-Castaño, PhD
principal investigator · Campus docent Sant Joan de Déu-Universitat de Barcelona

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion